Are you Dr. Wiesenhutter?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 69 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
950 W Ironwood Dr
Coeur D Alene, ID 83814Phone+1 208-765-5457Fax+1 208-765-6248
Summary
- Dr. Craig Wiesenhutter, MD is a rheumatologist in Coeur D Alene, Idaho. He is currently licensed to practice medicine in Idaho. He is affiliated with Kootenai Health, Benewah Community Hospital, and Bonner General Health.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Rheumatology, 1982 - 1983
University of Southern California/Los Angeles General Medical Center (USC/LA General)Fellowship, Rheumatology, 1980 - 1981- University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1976 - 1980
Albert Einstein College of MedicineClass of 1976
Certifications & Licensure
ID State Medical License 1983 - 2025- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PrimeSUITE EHR, Greenway Health, LLC, 2011-2013
- Fellow (FACR) American College of Rheumatology
Clinical Trials
- A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis Start of enrollment: 2005 Dec 01
Publications & Presentations
PubMed
- 122 citationsCevimeline for the Treatment of Xerostomia in Patients With Sjögren Syndrome: A Randomized TrialRose S. Fife, Walter F. Chase, Robin K. Dore, Craig W. Wiesenhutter, Peter B. Lockhart
Archives of Internal Medicine. 2002-06-10 - 49 citationsEvaluation of the Comparative Efficacy of Etoricoxib and Ibuprofen for Treatment of Patients With Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled TrialCraig W. Wiesenhutter, Judith A. Boice, Amy T Ko, Eric A. Sheldon, Frederick T. Murphy
Mayo Clinic Proceedings. 2005-04-01 - 85 citationsA randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumato...John D. Bradley, Alexei A Dmitrienko, Alan Kivitz, Oscar S Gluck, Arthur L. Weaver
The Journal of Rheumatology. 2005-03-01
Professional Memberships
- Fellow
